Primary Testicular Mucinous Adenocarcinoma-a Case Report and Review of Literature.

Orchidectomy Ovarian type epithelial tumor RPLND Scrotal ulceration Signet ring cells Testicular mucinous adenocarcinoma Testicular tumor

Journal

Indian journal of surgical oncology
ISSN: 0975-7651
Titre abrégé: Indian J Surg Oncol
Pays: India
ID NLM: 101532448

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 21 08 2023
accepted: 26 09 2023
pmc-release: 01 03 2025
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: ppublish

Résumé

Testicular tumors include germ cell tumors, sex cord stromal tumors, and ovarian type epithelial tumors. Testicular mucinous tumors belong to ovarian type epithelial tumors and are extremely rare with only 31 cases reported in literature so far. Among those, mucinous adenocarcinoma constitutes only 9 cases. There are no standard treatment guidelines owing to their rarity. We report a case of primary testicular mucinous adenocarcinoma managed by orchidectomy, chemotherapy, and retroperitoneal lymph node dissection. A 44-year-old gentleman presented with right testicular tumor with infiltration and ulceration of scrotal skin. Tumor markers were within normal limits. Patient underwent orchidectomy with excision of involved scrotal skin. HPE suggested mucinous adenocarcinoma of testis. Patient was then administered chemotherapy but had progression of disease and hence taken up for retroperitoneal, bilateral pelvic, and bilateral inguinal lymph node dissection with revision of spermatic cord. Patient recovered uneventfully and is on regular follow-up 6 months now since surgery. There are no standard guidelines for the management of mucinous adenocarcinoma of testis. It is essential to rule out mucinous carcinoma of gastrointestinal tract metastasizing to testis before labeling as primary mucinous adenocarcinoma of testis. Surgery remains the mainstay of treatment in metastasis confined to retroperitoneal and inguinal lymph nodes. Further studies are needed to identify optimal chemotherapy regimen for metastatic and adjuvant scenarios.

Identifiants

pubmed: 38511018
doi: 10.1007/s13193-023-01832-7
pii: 1832
pmc: PMC10948684
doi:

Types de publication

Case Reports

Langues

eng

Pagination

125-128

Informations de copyright

© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Déclaration de conflit d'intérêts

Conflict of InterestThe authors declare no competing interests.

Auteurs

Vijayabhaskar Ramakrishnan (V)

Department of Surgical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, India.

Kirushna Kumar (K)

Department of Radiation Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, India.

Krishna Kumar Rathnam (KK)

Department of Medical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, India.

Thalabathik Kumara Vikram (TK)

Department of Surgical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, India.

Niranjana Devi (N)

Department of Surgical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, India.
Department of Pathology, Meenakshi Mission Hospital and Research Centre, Madurai, India.

Classifications MeSH